Revolutionizing Kidney Care and Pharmacy Reimbursement: Strive Health's Funding Success and CVS Health's CostVantage Program

Revolutionizing Kidney Care and Pharmacy Reimbursement: Strive Health's Funding Success and CVS Health's CostVantage Program

Introduction:
In recent news, Strive Health, a digital health company specializing in kidney care, secured an impressive $166 million in Series C funding. Led by New Enterprise Associates and with participation from CVS Health Ventures, this round brings Strive's total venture funding to $386 million since its inception in 2018. Strive Health aims to provide comprehensive care for patients with chronic and end-stage kidney disease, utilizing a machine learning-enabled tech platform to personalize care plans. Simultaneously, CVS Health has introduced its CostVantage program for retail pharmacy reimbursement, which promises to stabilize and improve pharmacy margins. However, discrepancies in drug acquisition costs and reimbursements pose challenges for pharmacies, particularly concerning GLP-1 products. Let's explore the implications of these developments and their potential impact on the healthcare industry.

Strive Health: Revolutionizing Kidney Care
Strive Health's latest funding success demonstrates the growing recognition and need for innovative solutions in kidney care. With a focus on helping patients navigate the complexities of chronic and end-stage kidney disease, Strive leverages machine learning and data analytics to develop personalized care plans. By consolidating patient, medication, and claims data, Strive's tech platform offers a holistic approach to kidney care, improving patient outcomes, and reducing healthcare costs. The significant funding obtained by Strive indicates the potential for further expansion and the company's commitment to transforming the kidney care landscape.

CVS Health's CostVantage Program: A Game-Changer in Pharmacy Reimbursement
In response to the challenges faced by retail pharmacies, CVS Health has introduced the CostVantage program for retail pharmacy reimbursement. This innovative model, inspired by Mark Cuban's Cost Plus Drug Company (MCCPDC), incorporates a measure of pharmacy acquisition cost, a percentage margin, and a flat fee for pharmacy services. If widely accepted by payers and pharmacy benefit managers (PBMs), this program promises to enhance retail pharmacy margins and provide stability in an ever-changing healthcare landscape. By ensuring higher and more predictable margins, pharmacies can continue to deliver essential services while remaining financially viable.

The GLP-1 Conundrum: A Challenge for Pharmacies
While CVS Health's CostVantage program offers hope for improved pharmacy margins, pharmacies still face hurdles in acquiring certain medications, such as GLP-1 products. Wholesale acquisition costs (WAC) for brand-name drugs are typically discounted by six percentage points. However, GLP-1 products often have different pricing models, resulting in smaller discounts, such as WAC-2% (98% of WAC). This discrepancy means that pharmacies may end up purchasing GLP-1 products at a higher cost than the reimbursements received from PBMs. Consequently, pharmacies may find themselves operating at a loss when dispensing these medications.

Actionable Advice:

1. Diversify Revenue Streams: To mitigate the impact of lower reimbursements, pharmacies should explore opportunities to diversify their revenue streams. This could include expanding services, such as medication therapy management, immunizations, and specialty compounding, to generate additional income.

2. Advocate for Fair Reimbursement: Pharmacies should actively engage with PBMs and payers to advocate for fair reimbursement rates that align with the actual acquisition costs of medications. By highlighting the challenges faced in acquiring GLP-1 products and other medications, pharmacies can work towards a more equitable reimbursement system.

3. Embrace Technology and Automation: Investing in technology and automation can help pharmacies streamline operations, reduce costs, and improve efficiency. Implementing electronic health record systems, robotic dispensing technology, and inventory management software can optimize workflows and enhance profitability.

Conclusion:
The recent funding success of Strive Health highlights the growing demand for innovative solutions in kidney care. Simultaneously, CVS Health's CostVantage program offers hope for improving retail pharmacy margins. However, challenges persist, particularly concerning the acquisition costs and reimbursements of specific medications like GLP-1 products. To navigate these challenges successfully, pharmacies must diversify revenue streams, advocate for fair reimbursement rates, and embrace technology and automation. By addressing these issues, the healthcare industry can work towards providing better care for patients while ensuring the financial viability of pharmacies.